1999
DOI: 10.1074/jbc.274.9.5379
|View full text |Cite
|
Sign up to set email alerts
|

Tissue Factor Pathway Inhibitor-2 Is a Novel Mitogen for Vascular Smooth Muscle Cells

Abstract: A mitogen for growth-arrested cultured bovine aortic smooth muscle cells was purified to homogeneity from the supernatant of cultured human umbilical vein endothelial cells by heparin affinity chromatography and reverse-phase high performance liquid chromatography. This mitogen was revealed to be tissue factor pathway inhibitor-2 (TFPI-2), which is a Kunitz-type serine protease inhibitor. TFPI-2 was expressed in baby hamster kidney cells using a mammalian expression vector. Recombinant TFPI-2 (rTFPI-2) stimula… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
21
0

Year Published

2000
2000
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 35 publications
(23 citation statements)
references
References 15 publications
2
21
0
Order By: Relevance
“…Whereas the role of TFPI-2 in thoracic malignancies has not been systematically evaluated, Lakka et al (2000) observed that antisense to TFPI-2 enhances migration and invasiveness of A549 lung cancer cells in vitro. Although these observations suggest that TFPI-2 inhibits the malignant phenotype of cancer cells of diverse histologies, recent experiments by Neaud et al (2000) as well as Shinoda et al (1999) have shown that TFPI-2 is a potent mitogen for hepatocarcinoma as well as vascular smooth muscle cells. Collectively, these data indicate that the effects of TFPI-2 in cancer cells may be highly complex, and tissue specific.…”
Section: Discussionmentioning
confidence: 96%
“…Whereas the role of TFPI-2 in thoracic malignancies has not been systematically evaluated, Lakka et al (2000) observed that antisense to TFPI-2 enhances migration and invasiveness of A549 lung cancer cells in vitro. Although these observations suggest that TFPI-2 inhibits the malignant phenotype of cancer cells of diverse histologies, recent experiments by Neaud et al (2000) as well as Shinoda et al (1999) have shown that TFPI-2 is a potent mitogen for hepatocarcinoma as well as vascular smooth muscle cells. Collectively, these data indicate that the effects of TFPI-2 in cancer cells may be highly complex, and tissue specific.…”
Section: Discussionmentioning
confidence: 96%
“…More recently, it has been shown that HT-1080 fibrosarcoma cells expressing inactive R24Q TFPI-2 form tumors of 2-3 times larger in athymic mice compared to wild-type TFPI-2 expressing counterparts (Chand et al, 2004). Interestingly, TFPI-2 has been reported to stimulate the growth of vascular smooth muscle cells (Shinoda et al, 1999) and retinal pigment epithelial cells (Tanaka et al, 2004), implying cell type-specific role of TFPI-2 in cellular proliferation. These diverse biological effects of TFPI-2 on various cell types as well as the therapeutic potential of restoring TFPI-2 function in pancreatic cancer cells should be carefully evaluated in future studies.…”
Section: Discussionmentioning
confidence: 99%
“…8 Thus the up-regulation of TFPI-2 by the differentiation of endothelial cells might have a dual role of limiting the extent of matrix degradation and recruiting or promoting the proliferation of mural cells, leading to the assembly of the new vessel wall.…”
Section: Discussionmentioning
confidence: 99%